Mitral Regurgitation is the third most common cardiovascular disease that occurs when there is backward flow of blood across the mitral valve. It is highly prevalent, debilitating for patients, and deadly if untreated. The market is expected to be larger than the TAVR market, currently a $6B market.
The CardioMech device is an artificial chord that is designed to reduce or eliminate regurgitation and to restore the native anatomy. This catheter-based therapy is intended to be a simple and straightforward procedure and an alternative therapy option for both patients eligible for open-heart surgery and those considered surgically ineligible. Therefore, the CardioMech device can potentially reduce the need for open-heart surgery and may lessen the need for watchful waiting in younger and healthier patients.
Caution: Investigational device. Limited by law to investigational use.
Company Details
- Employees
- 9
- Founded
- -
- Address
- Trondheim, - 7030, No
- in****@****ech.com
- Industry
- Medical Equipment Manufacturing
- NAICS
-
Medical Equipment and Supplies ManufacturingSurgical and Medical Instrument ManufacturingSurgical Appliance and Supplies ManufacturingDental Equipment and Supplies ManufacturingOphthalmic Goods ManufacturingDental Laboratories
- Website
- cardiomech.com
- HQ
- Trondheim, -
Cardiomech As Questions
Cardiomech As's website is cardiomech.com
Cardiomech As's LinkedIn profile is https://no.linkedin.com/company/cardiomech
Cardiomech As has
9 employees.
View email and phone details for 9
employees at Cardiomech As.
Cardiomech As's industry is
Medical Equipment Manufacturing
Cardiomech As's top competitors are
Muybridge,
Sonair,
Sensibel,
Coremedic,
Nyra Medical,
Cardiac Dimensions,
Ably Medical,
Red Rover Interactive,
Esmart Systems,
Moray Medical.
Cardiomech As's support email address is info@cardiomech.com
Cardiomech As's categories are Medical Equipment Manufacturing
Cardiomech As's founding year is 2015
